Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 avr. 2025 04h09 HE | Source: Research and Markets

mRNA Vaccine and Therapeutics Market Report 2025-2035: 430+ Patents Filed, Signaling Robust Growth in mRNA Intellectual Property

Dublin, April 01, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035, by Application Area, Target Disease Indication (Influenza,...
18 mars 2025 05h20 HE | Source: Research and Markets

mRNA Vaccines Market Trends and Competition Analysis 2025-2030: Revenues are Projected to Nearly Double, Growing by ~$8 Billion

Dublin, March 18, 2025 (GLOBE NEWSWIRE) -- The "mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, End-User,...
16 janv. 2025 04h10 HE | Source: Research and Markets

United States Influenza Vaccines Market Research 2025 Featuring Sanofi Pasteur, GSK, Seqirus, AstraZeneca - Size, Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts to 2033

Dublin, Jan. 16, 2025 (GLOBE NEWSWIRE) -- The "United States Influenza Vaccines Market Report 2025: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts to...
26 déc. 2024 02h00 HE | Source: Polaris Market Research & Consulting LLP

mRNA Vaccines and Therapeutics Market Expected to Reach USD 253.83 Billion By 2034, With 16.7% CAGR From 2025 to 2034 | PMR

New York, USA, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Market Overview The market for mRNA vaccines and therapeutics is poised to grow, according to the latest research study by Polaris Market Research....
11 déc. 2024 04h18 HE | Source: Research and Markets

mRNA Vaccines and Therapeutics Industry Forecast to Generate Over $72 Billion in Revenues by 2032 - Breakdown by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region

Dublin, Dec. 11, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccines and Therapeutics Market by Vaccine Type, Treatment Type, Vaccine Manufacturing, Application, End-user, and Region 2024-2032" report has...
29 oct. 2024 10h59 HE | Source: Research and Markets

United States Influenza Vaccines Market Report 2025: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts 2019-2023 & 2024-2033

Dublin, Oct. 29, 2024 (GLOBE NEWSWIRE) -- The "United States Influenza Vaccines Market Report 2025: Industry Size, Market Shares Data, Latest Trends, Insights, Growth Potential, CAGR Forecasts to...
26 sept. 2024 07h21 HE | Source: Research and Markets

mRNA Vaccine and Therapeutics Market Global Report to 2035, with Profiles of Arcturus Therapeutics, BioNTech, CureVac, Ethris, Immorna, Moderna, Providence Therapeutics and Suzhou Abogen Biosciences

Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "mRNA Vaccine and Therapeutics Market Industry Trends and Global Forecasts to 2035: Distribution by Application Area, Target Disease Indication and...
10 sept. 2024 07h12 HE | Source: Research and Markets

Adult Vaccine Market Forecasts Report and Competitive Landscape 2024-2032 Featuring GlaxoSmithKline, AstraZeneca, Sanofi Pasteur, Pfizer, and CSL

Dublin, Sept. 10, 2024 (GLOBE NEWSWIRE) -- The "Adult Vaccine Market Report, Forecast by Disease, Countries and Company Analysis, 2024-2032" report has been added to ResearchAndMarkets.com's...
28 août 2024 04h45 HE | Source: Research and Markets

COVID-19 Vaccines Business Research Report 2024: Doses to Reach a Projected 4.2 Billion by 2025 - Global Market Forecast to 2030

Dublin, Aug. 28, 2024 (GLOBE NEWSWIRE) -- The "COVID-19 Vaccines - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global market for COVID-19...
16 août 2024 06h45 HE | Source: BioNTech SE

Pfizer und BioNTech geben Update zu mRNA-basiertem Kombinationsimpfstoffprogramm gegen Grippe und COVID-19 bei Personen im Alter von 18 bis 64 Jahren bekannt

Pfizers und BioNTechs Kombinationsimpfstoffkandidat gegen Grippe und COVID-19 hat in einer Phase-3-Studie eines ihrer beiden primären Ziele zur Immunogenität erreichtDie Studie erreichte eines ihrer...

Page suivante keyboard_arrow_right